Human/Mouse/Rat FKBP52 Antibody

Detection of Human/Mouse/Rat FKBP52 by Western Blot.

Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line. PVDF membrane was probed with 0.3 µg/mL of Human/Mouse/Rat FKBP52 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF4095) followed by HRP-conjugated Anti‑Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for FKBP52 at approximately 52 kDa (as indicated). This experiment was conducted using Immunoblot Buffer Group 2.

Detection of FKBP52 by Western Blot

Effect of low-dose tacrolimus, L-NAME or mifepristone and their combination formulations on the levels of expression and cellular localization of FKBP52 and PGR in HTR-8/SVneo cells. (A) Representative confocal fluorescent microscope images of monolayers of confluent HTR-8/SVneo cells treated for 24 h with low-dose tacrolimus (10 ng/mL), L-NAME or a combination of both. Cells were stained with antibodies to PGR (red channel) and FKBP52 (green channel) and cell images were captured and analyzed for their fluorescent intensity using Quorum Wave Effects Spinning disc confocal microscope. Nuclei were counterstained with DAPI (blue channel) and the colocalization of PGR and FKBP52 appears as yellow on the overlay images. (B) Histogram depicting differences in the intensity of colocalization of PGR and FKBP52 (yellow channel) showing significant effect of low-dose tacrolimus on the expression of the PGR-FKBP52 complex in treated HTR-8/SVneo cells. (C) Representative WB images and associated histograms of the expression levels of FKBP52 protein in the tacrolimus- and L-NAME-treated HTR-8/SVneo cells. Note the statistically significant effects (p < 0.001) of tacrolimus in antagonizing the suppressive actions of L-NAME and those of mifepristone on the protein expression of FKBP52 in the HTR-8/SVneo cells. Data in (B,C) are represented as the mean with error bars representing S.D. Scale bars in A = 15 μm. Mifepristone was used to determine the mode of action of tacrolimus in potentiating the PGR signaling in HTR-8/SVneo cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35955565), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FKBP52 by Western Blot

Effect of low-dose tacrolimus, L-NAME or mifepristone and their combination formulations on the levels of expression and cellular localization of FKBP52 and PGR in HTR-8/SVneo cells. (A) Representative confocal fluorescent microscope images of monolayers of confluent HTR-8/SVneo cells treated for 24 h with low-dose tacrolimus (10 ng/mL), L-NAME or a combination of both. Cells were stained with antibodies to PGR (red channel) and FKBP52 (green channel) and cell images were captured and analyzed for their fluorescent intensity using Quorum Wave Effects Spinning disc confocal microscope. Nuclei were counterstained with DAPI (blue channel) and the colocalization of PGR and FKBP52 appears as yellow on the overlay images. (B) Histogram depicting differences in the intensity of colocalization of PGR and FKBP52 (yellow channel) showing significant effect of low-dose tacrolimus on the expression of the PGR-FKBP52 complex in treated HTR-8/SVneo cells. (C) Representative WB images and associated histograms of the expression levels of FKBP52 protein in the tacrolimus- and L-NAME-treated HTR-8/SVneo cells. Note the statistically significant effects (p < 0.001) of tacrolimus in antagonizing the suppressive actions of L-NAME and those of mifepristone on the protein expression of FKBP52 in the HTR-8/SVneo cells. Data in (B,C) are represented as the mean with error bars representing S.D. Scale bars in A = 15 μm. Mifepristone was used to determine the mode of action of tacrolimus in potentiating the PGR signaling in HTR-8/SVneo cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35955565), licensed under a CC-BY license. Not internally tested by R&D Systems.